JPH06287132A - Medicine for improving occlusal trauma - Google Patents
Medicine for improving occlusal traumaInfo
- Publication number
- JPH06287132A JPH06287132A JP9853293A JP9853293A JPH06287132A JP H06287132 A JPH06287132 A JP H06287132A JP 9853293 A JP9853293 A JP 9853293A JP 9853293 A JP9853293 A JP 9853293A JP H06287132 A JPH06287132 A JP H06287132A
- Authority
- JP
- Japan
- Prior art keywords
- flurbiprofen
- occlusal
- occlusal trauma
- improving
- trauma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、口腔内に適応する咬合
性外傷の治療剤に関する。さらにいえば、咬合性外傷に
より生じる歯根膜結合組織の変性・壊死を改善し、歯の
動揺を治療するのに有効な口腔内に適応する治療用剤に
関する。TECHNICAL FIELD The present invention relates to a therapeutic agent for occlusal trauma adapted to the oral cavity. More specifically, the present invention relates to a therapeutic agent that improves degeneration / necrosis of periodontal connective tissue caused by occlusal trauma and is effective in the oral cavity for treating tooth movement.
【０００２】[0002]
【従来の技術および問題点】近年、歯周疾患は、高齢化
社会における重要な課題のひとつとされ、これに対する
治療および予防法の確立が望まれている。咬合性外傷は
歯列不正、早期接触、歯ぎしりなど物理的な咬合不良に
よる歯に対する負荷が、歯根膜や歯槽骨を傷つけること
により発症する。負荷を受けた歯の歯根膜は断裂・変性
などを起こし、コラーゲン線維構造が破壊される。その
結果、患者は歯の動揺感や咬合時の疼痛を感じることと
なる。咬合性外傷の治療としては、原因である外傷性咬
合に対処することが先決であり，咬合調整が施される。
すなわち歯冠の削合および修復により、咬合時にかかる
負荷を調整する治療がなされるが、治療が終了し、症状
が軽快するまでには長期間を要する。この間、患者は歯
の動揺、咬合時の疼痛などの苦痛を受け続けなければな
らないが、これらの症状に対処する薬物治療は十分では
ない。2. Description of the Related Art Recently, periodontal disease has been regarded as one of the important problems in an aging society, and it is desired to establish a treatment and prevention method for it. Occlusal trauma is caused by damage to the periodontal ligament or alveolar bone due to a load on the tooth due to physical occlusion such as malalignment of teeth, early contact, and bruxism. The periodontal ligament of the loaded tooth causes rupture and degeneration, and the collagen fiber structure is destroyed. As a result, the patient feels a feeling of tooth movement and pain during occlusion. As a treatment for occlusal trauma, the traumatic occlusion, which is the cause, is dealt with first, and occlusal adjustment is performed.
That is, although the treatment for adjusting the load applied at the time of occlusion is performed by cutting and repairing the crown, it takes a long period of time until the treatment is completed and the symptoms are relieved. During this time, the patient must continue to suffer from tooth sway, occlusal pain, etc., but drug treatment to address these symptoms is not sufficient.
【０００３】本発明口腔用組成物に有効成分として配合
される非ステロイド系抗炎症剤は、解熱鎮痛剤として開
発され、歯周炎による歯槽骨吸収の抑制作用を有するこ
とが知られている。また特開６０−６１５２４によれば
歯槽骨減少の抑制に有効な局所投与剤型が提示されてい
る。また、歯根膜炎の治療において鎮痛消炎を目的に短
期間の内服投与が行われている。しかし、本願のような
咬合性外傷の治療に関する技術は知られていない。The non-steroidal anti-inflammatory agent added to the oral composition of the present invention as an active ingredient has been developed as an antipyretic analgesic and is known to have an action of suppressing alveolar bone resorption caused by periodontitis. Further, Japanese Patent Laid-Open No. 60-61524 discloses a local administration dosage form effective for suppressing alveolar bone loss. Further, in the treatment of periodontitis, oral administration has been performed for a short period of time for the purpose of analgesic and anti-inflammatory. However, no technique related to treatment of occlusal trauma such as the present application is known.
【０００４】[0004]
【問題点を解決するための手段】本発明者らは感染症に
よって発症する歯周炎とは異なり歯列不正等の物理的原
因によって発症する咬合性外傷に対する薬物療法を研究
した。その結果、意外にもフルルビプロフェン、イブプ
ロフェン、ケトプロフェン、ナプロキセン、ピロキシカ
ムが、咬合性外傷による歯根膜結合組織の変性・壊死を
改善し、歯の動揺を改善することを見いだし発明を完成
した。[Means for Solving the Problems] The present inventors have studied drug therapy for occlusal trauma caused by physical causes such as malalignment of teeth, unlike periodontitis caused by infection. As a result, they have surprisingly found that flurbiprofen, ibuprofen, ketoprofen, naproxen, and piroxicam improve degeneration and necrosis of periodontal connective tissue due to occlusal trauma and improve tooth sway, and completed the invention.
【０００５】即ち、本願発明は、非ステロイド系抗炎症
剤の１種以上を配合したことを特徴とする咬合性外傷治
療剤である。本願発明に用いる非ステロイド系抗炎症剤
は、フルルビプロフェン、イブプロフェン、ケトプロフ
ェン、ナプロキセン、ピロキシカム等の非ステロイド系
抗炎症であり、特に好ましくはフルルビプロフェン、イ
ブプロフェンである。これらの抗炎症剤の配合量は０．
１〜１０重量％が適当であり、好ましくは０．５〜５重
量％である。本願発明の投与形態は口腔内に適用できる
物であれば良く、例えばゲル、ペースト、貼付剤、歯周
ポケット注入剤等が好ましい。本薬物は経口投与によっ
てもこれらの効果を奏するが、投与期間が長期にわたる
ことから、胃腸障害等の副作用を伴う危険があり、投与
形態として好ましくない。That is, the present invention is a therapeutic agent for occlusal trauma characterized by containing one or more non-steroidal anti-inflammatory agents. The non-steroidal anti-inflammatory drug used in the present invention is a non-steroidal anti-inflammatory drug such as flurbiprofen, ibuprofen, ketoprofen, naproxen and piroxicam, and particularly preferably flurbiprofen and ibuprofen. The blending amount of these anti-inflammatory agents is 0.
1-10% by weight is suitable, preferably 0.5-5% by weight. The dosage form of the present invention may be any one that can be applied to the oral cavity, and for example, gel, paste, patch, periodontal pocket injection, etc. are preferable. Although the drug exhibits these effects by oral administration, it is not preferable as a dosage form because of its long administration period, which may cause side effects such as gastrointestinal disorders.
【０００６】さらに、本発明組成物に配合される他の成
分としては、その口腔用組成物の種類に応じ、適宜の公
知の成分が用いられる。例えば、貼付剤は、口腔内の湿
潤粘膜に貼付されて優れた貼付性を有し、投与薬剤の流
出防止、口腔内粘膜損傷部の被覆保護を行うフィルム状
の付着体からなる口腔内製剤である。貼付剤の一例とし
ては、粘膜に付着性を有する水溶性高分子物質、例えば
ヒドロキシプロピルセルロース、カルボキシビニルポリ
マー等をフィルム状に成形したものが挙げられる。Further, as other components to be added to the composition of the present invention, appropriate known components are used depending on the kind of the oral composition. For example, the patch is an intraoral preparation consisting of a film-like adherent that is applied to the moist mucous membrane in the oral cavity and has excellent adhesiveness, prevents the outflow of the administered drug, and protects the damaged part of the oral mucosa from coating. is there. As an example of the patch, a water-soluble polymer substance having adhesiveness to mucous membrane, for example, hydroxypropyl cellulose, carboxyvinyl polymer or the like, which is formed into a film, can be mentioned.
【０００７】[0007]
【実施例】以下に実施例、試験例をあげて本願発明を具
体的に説明する。 （１）コラーゲン線維の保持作用および歯の動揺治療効
果 ゴールデンハムスター５０匹を用いた。厚さ０．１ｍｍ
のゴム片を第１臼歯と第２臼歯の歯間部に挿入し物理的
圧迫を加えることにより、実験的に咬合性外傷を惹起し
た。これを５群に分け、４群にそれぞれフルルビプロフ
ェン０．０１％、０．１％、１％、１０％を含有する実
施例３記載の組成物０．２ｇを１日１回歯肉辺縁部に投
与し、実験群とした。残りの１群には、フルルビプロフ
ェンを含有しないプラセボを投与し、プラセボ群とし
た。別の同週齢個体５匹を通常飼育し、健常群とした。
これらの群について下記の評価を行った。EXAMPLES The present invention will be described in detail below with reference to examples and test examples. (1) Collagen fiber retention action and tooth movement treatment effect 50 golden hamsters were used. Thickness 0.1 mm
The occlusal trauma was experimentally induced by inserting the rubber piece of No. 3 into the interdental part of the first molar and the second molar and applying physical pressure. This was divided into 5 groups, and 0.2 g of the composition described in Example 3 containing 0.01%, 0.1%, 1%, and 10% of flurbiprofen in 4 groups was once daily administered to the gingival margin. It was administered to the edge and used as an experimental group. A placebo containing no flurbiprofen was administered to the remaining one group to form a placebo group. Five other individuals of the same age were usually bred to make a healthy group.
The following evaluations were performed on these groups.
【０００８】（１−Ａ）歯の動揺治療作用 試験開始３週間後に麻酔下で第１臼歯、第２臼歯に対し
頬舌方向に頬側あるいは舌側から５０ｍｇの力を加えな
がら実体顕微鏡下で歯の可動距離を測定した。実際の値
に換算された可動距離をもって、歯の動揺度とした。 （１−Ｂ）コラーゲン線維の保持作用 ３週間の飼育期間終了後、常法に従い下顎臼歯部のパラ
フィン包埋組織標本を作成し、光学顕微鏡により第１臼
歯と第２臼歯の歯間部のコラーゲン線維の走向状態を観
察した。コラーゲン線維走向の崩壊の程度を、健常群と
比較して次の基準により評価し、コラーゲン線維保持作
用についての有効性を判定した。 結果を第１表および
第２表に示す。(1-A) Tooth sway treatment effect Under a stereoscopic microscope, three weeks after the start of the test, a force of 50 mg was applied to the first and second molars in the buccolingual direction from the buccal side or the lingual side under anesthesia. The movable distance of the tooth was measured. The moving distance converted to the actual value was used as the tooth mobility. (1-B) Retaining action of collagen fibers After the end of the 3-week breeding period, a paraffin-embedded tissue sample of the mandibular molar was prepared in accordance with a conventional method, and the collagen of the interdental part of the first and second molars was observed by an optical microscope. The running state of the fibers was observed. The degree of collapse of collagen fiber strike was evaluated by the following criteria in comparison with the healthy group, and the effectiveness of collagen fiber retention was determined. The results are shown in Tables 1 and 2.
【０００９】[0009]
【表１】 [Table 1]
【００１０】[0010]
【表２】 [Table 2]
【００１１】（評価基準） −：コラーゲン線維走向の崩壊が、認められない。 ±：コラーゲン線維走向の崩壊が、上皮直下に軽微に認
められる。 ＋：コラーゲン線維の溶解・消失が、上皮下に限局して
認められる。 ＋＋：コラーゲン線維走向の崩壊が、歯槽頂部の骨辺縁
に及んでいる。 ＋＋＋：コラーゲン線維走向の崩壊が、歯根膜内部にま
で及んでいる。(Evaluation Criteria): Collapse of collagen fiber strike is not observed. ±: Collapse of collagen fiber strike is slightly observed just below the epithelium. +: Dissolution / disappearance of collagen fibers is observed locally in the subepithelium. ++: Collagen fiber strike disruption extends to the alveolar crest bone margin. ++++: Collagen fiber strike disruption extends into the periodontal ligament.
【００１２】第１表および第２表に明らかなごとく、フ
ルルビプロフェンは実験的に発症させた咬合性外傷によ
る歯根膜中のコラーゲン線維構造の破壊を抑制すること
により、歯の動揺の進行を抑制する作用が見られた。 （２）人による歯の動揺改善作用 咬合性外傷を呈するヒト５名に対し、上顎より隣接しな
い被験部位２箇所を選び、一方を薬物投与部位としてフ
ルルビプロフェン１％含有の実施例２記載の組成物０．
５ｇを１日２回辺縁歯肉に塗布した。他方をプラセボ側
としてフルルビプロフェンを含有しないプラセボを塗布
した。実験開始日より１週間毎に、歯の動揺度測定装置
ペリオテストＲ（シーメンス社製）を用いてＷ．Ｓｃｈ
ｕｌｔｅらの方法（Ｊ．Ｐｅｒｉｏｄｏｎｔ． Ｒｅ
ｓ． １９９２；２７：１８４−１９０）に従って、歯
の頬舌方向の動揺度を測定した。測定結果をペリオテス
ト値として第３表に示す。第３表により明らかなごと
く、本発明に含まれるフルルビプロフェンは、咬合性外
傷における歯の動揺を改善する作用が見られた。As is clear from Tables 1 and 2, flurbiprofen suppresses the destruction of collagen fiber structure in the periodontal ligament due to experimentally generated occlusal trauma, thereby promoting tooth sway. The effect of suppressing (2) Human tooth sway improving effect For 5 humans with occlusal trauma, 2 test sites not adjacent to the upper jaw were selected, and one of them was used as a drug administration site and 1% of flurbiprofen was contained. Composition 0.
5 g was applied to the marginal gingiva twice a day. The other placebo side was applied with placebo without flurbiprofen. Every week after the start date of the experiment, the tooth movement was measured using a tooth motion measuring device PERIODEST R (manufactured by Siemens). Sch
ulte et al. (J. Periodont. Re
s. 1992; 27: 184-190), the degree of tooth mobility in the cheek-lingual direction was measured. The measurement results are shown in Table 3 as period test values. As is clear from Table 3, flurbiprofen contained in the present invention was found to have an action of improving the agitation of teeth in occlusal trauma.
【００１３】[0013]
【表３】 [Table 3]
【００１４】［実施例１：歯肉適用貼付剤］以下の成分
を水／エタノールの混液に溶解し、これを常法により伸
展し、５０μｍの厚さのフィルム状付着体を製造し、乾
燥した。他方、酢酸ビニルポリマーをエタノールに溶解
して常法により伸展し４０μｍの厚さのフィルム状支持
体を作り、乾燥する。支持体と付着体を熱圧着して歯肉
適用貼付剤を作成した。 成 分 配合量（重量％） カルボキシビニルポリマー ５０．０ ヒドロキシプロピルセルロース ４８．０ フルルビプロフェン ２．０ 合計 １００．０[Example 1: Patch for Gingival Application] The following components were dissolved in a water / ethanol mixed solution, which was spread by a conventional method to prepare a film-like adherent having a thickness of 50 μm and dried. On the other hand, a vinyl acetate polymer is dissolved in ethanol and spread by a conventional method to form a film-like support having a thickness of 40 μm, and dried. The support and the adherent were thermocompression bonded to prepare a gingival application patch. Ingredients Blending amount (wt%) Carboxy vinyl polymer 50.0 Hydroxypropyl cellulose 48.0 Flurbiprofen 2.0 Total 100.0
【００１５】［実施例２：口腔用パスタ］以下の組成に
より常法により口腔用パスタを製造した。 成 分 配合量（重量％） ポリオキシエチレンモノステアレート ２．０ ソルビタンモノオレート ２．０ セチルアルコール ２．０ パルミチルアルコール ３．０ プロピレングリコール １５．０ カルボキシメチルセルロース ５．０ ゼラチン １．０ サッカリン ０．２ 香料 ０．３ フルルビプロフェン １．０ 水 残部 合計 １００[Example 2: Oral pasta] An oral pasta was produced by a conventional method with the following composition. Ingredient content (wt%) Polyoxyethylene monostearate 2.0 Sorbitan monooleate 2.0 Cetyl alcohol 2.0 Palmityl alcohol 3.0 Propylene glycol 15.0 Carboxymethyl cellulose 5.0 Gelatin 1.0 Saccharin 0 .2 Fragrance 0.3 Flurbiprofen 1.0 Water Balance 100
【００１６】実施例３（口腔用軟膏） 以下の組成により常法により口腔用軟膏を製造した。 Example 3 (Oral Ointment) An oral ointment was produced by the usual method with the following composition.
【００１７】これらの実施例においてフルルビプロフェ
ンを配合した処方例を示したが、同様の処方において、
薬効剤をイブプロフェン、ケトプロフェン、ナプロキセ
ン、ピロキシカムに置き換えた処方も製造できる。In these examples, prescription examples in which flurbiprofen was blended were shown, but in the same prescription,
It is also possible to manufacture a formulation in which the medicinal agent is replaced with ibuprofen, ketoprofen, naproxen, piroxicam.
【００１８】[0018]
【発明の効果】本発明は、咬合性外傷による歯根膜結合
組織の変性・壊死を改善し、歯牙の動揺を防止できる。INDUSTRIAL APPLICABILITY The present invention can improve the degeneration and necrosis of periodontal connective tissue due to occlusal trauma and prevent tooth movement.
Claims (3)
合したことを特徴とする咬合性外傷治療剤。1. A therapeutic agent for occlusal trauma, which comprises one or more non-steroidal anti-inflammatory agents.
０．１〜１０．０重量％である請求項１記載の治療剤。2. The therapeutic agent according to claim 1, wherein the compounding amount of the non-steroidal anti-inflammatory agent is 0.1 to 10.0% by weight.
ビプロフェン、イブプロフェン、ケトプロフェン、ナプ
ロキセン、ピロキシカムである請求項１記載の治療剤。3. The therapeutic agent according to claim 1, wherein the non-steroidal anti-inflammatory agent is flurbiprofen, ibuprofen, ketoprofen, naproxen, piroxicam.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5098532A JP2895343B2 (en) | 1993-03-31 | 1993-03-31 | Treatment for occlusal trauma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5098532A JP2895343B2 (en) | 1993-03-31 | 1993-03-31 | Treatment for occlusal trauma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06287132A true JPH06287132A (en) | 1994-10-11 |
| JP2895343B2 JP2895343B2 (en) | 1999-05-24 |
Family
ID=14222292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5098532A Expired - Fee Related JP2895343B2 (en) | 1993-03-31 | 1993-03-31 | Treatment for occlusal trauma |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2895343B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221323B2 (en) | 2007-08-03 | 2012-07-17 | Cardiac Pacemakers, Inc. | Using acoustic energy to compute a lung edema fluid status indication |
| WO2017029710A1 (en) * | 2015-08-18 | 2017-02-23 | 合同会社Ｐｈａｒｍａ Ｓｅｅｄｓ Ｃｒｅａｔｅ | Oral composition containing nsaid or heparin compound |
-
1993
- 1993-03-31 JP JP5098532A patent/JP2895343B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221323B2 (en) | 2007-08-03 | 2012-07-17 | Cardiac Pacemakers, Inc. | Using acoustic energy to compute a lung edema fluid status indication |
| WO2017029710A1 (en) * | 2015-08-18 | 2017-02-23 | 合同会社Ｐｈａｒｍａ Ｓｅｅｄｓ Ｃｒｅａｔｅ | Oral composition containing nsaid or heparin compound |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2895343B2 (en) | 1999-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heithersay | Treatment of invasive cervical resorption: An analysis of results using topical application of trichioracetic acid, curettage, and restoration. | |
| Müller et al. | Gingival dimensions after root coverage with free connective tissue grafts | |
| US7115252B2 (en) | Therapeutic compositions and methods of use thereof | |
| Ozcelik et al. | Iatrogenic trauma to oral tissues | |
| Coll et al. | Evaluation of a one-appointment formocresol pulpectomy technique for primary molars | |
| EP0404558A1 (en) | Liquid polymer composition, and method of use | |
| Barkin et al. | Acute allergic reaction to eugenol | |
| BR112020002106B1 (en) | GEL COMPOSITION, PREPARATION METHOD AND USE | |
| Alquthami et al. | Successful management of teeth with different types of endodontic-periodontal lesions | |
| CA2141056C (en) | Treatment of dentoalveolar infections with taurolidine and/or taurultam | |
| Shah | Paediatric dentistry-novel evolvement | |
| JP4824954B2 (en) | Oral composition for the treatment of stomatitis | |
| US20190008729A1 (en) | Dental composition and method of direct pulp capping | |
| JP2895343B2 (en) | Treatment for occlusal trauma | |
| JPH0645535B2 (en) | Composition for treating alveolar bone metabolism | |
| Sjöström et al. | Tissue necrosis after subgingival irrigation with fluoride solution | |
| Mohamed et al. | Clinical evaluation of intramasseteric versus submucosal dexamethasone administration after surgical removal of impacted mandibular third molar | |
| Brignardello-Petersen | Aromatherapy may be effective in reducing anxiety in patients undergoing dental treatment | |
| US20070020200A1 (en) | Therapeutic compositions and methods of use thereof | |
| Rabie et al. | Treatment of a maxillary canine with external inflammatory root resorption | |
| JP3259957B2 (en) | Periodontal disease treatment | |
| Prakash et al. | Unusual representation of oral pyogenic granuloma in mandible mimicking malignancy: Report of two cases | |
| RU2204983C2 (en) | Material for temporary fixation of fixed partial dentures | |
| Manakou et al. | Subgingival foreign body embedment in a preschool child: management with three and a half years follow-up | |
| JPH0637379B2 (en) | Topical for treatment of periodontal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19990202 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |